psychiatric disorders

Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder

mycolabadmin

This review examines how edible mushrooms, particularly Lion’s mane, Reishi, and Caterpillar mushroom, might help treat depression as part of a dietary approach. These mushrooms contain compounds that may influence brain chemistry, especially serotonin levels, which are important for mood regulation. While early studies show promising results, especially for Lion’s mane, more research is needed to confirm these benefits in larger groups of patients.

Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment

mycolabadmin

This research examined young genetically modified mice that lack the SAPAP3 gene to understand early signs of obsessive-compulsive disorder-like behavior. The study found that these juvenile mice showed anxiety-like behaviors before developing the excessive grooming typical of the adult model. Surprisingly, psilocybin treatment—which works in adult mice—did not help reduce anxiety in the younger mice, suggesting that the brain needs to mature for this treatment to be effective.

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

mycolabadmin

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

mycolabadmin

This review examines how psychedelic substances like psilocybin and LSD affect brain structure and function. Research shows these compounds can increase BDNF (a protein crucial for brain health) and promote the growth of new neurons and connections between brain cells. These biological changes may explain why psychedelics have shown promise in treating depression and anxiety, with effects lasting weeks after a single dose.

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

mycolabadmin

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder

mycolabadmin

Researchers gave eight patients with body dysmorphic disorder (an excessive preoccupation with appearance flaws) a single dose of psilocybin and measured their brain activity before and after treatment. They found that psilocybin increased communication between key brain regions involved in decision-making and attention control. Patients whose brains showed these changes experienced significant symptom improvement within a week, suggesting psilocybin may help by enhancing mental flexibility and emotional regulation in BDD.

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses

mycolabadmin

Researchers used computer-based analysis to understand how psilocybin, a compound found in certain mushrooms, might help prevent suicide. They identified four key proteins that psilocybin interacts with and found that it works through serotonin and calcium signaling pathways in the brain, which are known to be involved in depression and suicidal behavior. While these findings are promising, more research is needed to confirm these effects in humans before psilocybin can be used clinically for suicide prevention.

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Research Topic: psychiatric disorders